Novocure (NVCR) Intriguing TTFields Potential; Luther King Ups Stake In Inventure Foods (SNAK)


NovoCure Ltd. (Nasdaq:NVCR) shares climbed more than 20% in the extended session Friday after the company said that glioblastoma patients lived significantly longer when treated with a combination therapy of its tumor treating fields (TTFields) Optune with chemotherapy (bevacizumab), compared with patients who received chemotherapy alone

NVCR stock closed at $22.04, down $0.37 (or -1.65%), and 251,530 of its shares exchanged hands during the day

Novocure, an oncology company, has 83.62M Shares Outstanding, Market Capitalization (intraday) of $1.84B and NVCR stock 52-week range is between $15.01 and $30.89 per share



Luther King Capital Management Corp. disclosed in a regulatory filing ( SC 13D/A ) with the Securities and Exchange Commission (SEC) an 8.9% stake (1,749,672 shares) in Inventure Foods, Inc. (Nasdaq:SNAK), representing an increase from the 1,531,650 shares disclosed by the investment advisory firm on November 12, 2015.

Inventure Foods, a leading specialty food marketer and manufacturer, recently reported third quarter 2015 net revenues of $69.9 million and a net loss of $(1.7) million, or $(0.09) per share for the period

SNAK stock finished Friday’s market activity at $6.73, down $0.01 (or -0.15%), with a total volume of 218,666 shares traded

The company has 19.61M Shares Outstanding, Market Capitalization (intraday) of $131.97M and SNAK stock one-year range is $6.57 – $14.11 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at